Morgan Stanley Avrobio, Inc. Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Oct 17, 2024
BUY
$1.15 - $1.48 $183,665 - $236,369
159,709 New
159,709 $204,000
Q1 2024

Aug 16, 2024
SELL
$1.15 - $1.48 $538,832 - $693,454
-468,550 Reduced 74.58%
159,709 $204,000
Q1 2024

May 15, 2024
SELL
$1.15 - $1.48 $538,832 - $693,454
-468,550 Reduced 74.58%
159,709 $204,000
Q4 2023

Aug 16, 2024
BUY
$1.22 - $1.62 $766,475 - $1.02 Million
628,259 New
628,259 $854,000
Q4 2023

Feb 13, 2024
BUY
$1.22 - $1.62 $130,613 - $173,437
107,060 Added 20.54%
628,259 $854,000
Q3 2023

Nov 15, 2023
SELL
$0.98 - $1.62 $517,509 - $855,475
-528,071 Reduced 50.33%
521,199 $802,000
Q2 2023

Aug 14, 2023
BUY
$0.58 - $1.31 $490,926 - $1.11 Million
846,425 Added 417.28%
1,049,270 $996,000
Q1 2023

May 15, 2023
SELL
$0.76 - $1.82 $258,842 - $619,859
-340,582 Reduced 62.67%
202,845 $202,000
Q4 2022

Feb 14, 2023
BUY
$0.64 - $0.91 $20,292 - $28,853
31,707 Added 6.2%
543,427 $385,000
Q3 2022

Nov 14, 2022
SELL
$0.68 - $1.11 $15,881 - $25,924
-23,355 Reduced 4.36%
511,720 $329,000
Q2 2022

Oct 27, 2022
BUY
$0.75 - $1.33 $50,562 - $89,664
67,417 Added 14.42%
535,075 $492,000
Q2 2022

Aug 15, 2022
BUY
$0.75 - $1.33 $50,562 - $89,664
67,417 Added 14.42%
535,075 $492,000
Q1 2022

Oct 27, 2022
SELL
$1.29 - $4.04 $86,967 - $272,364
-67,417 Reduced 12.6%
467,658 $617,000
Q1 2022

May 13, 2022
BUY
$1.29 - $4.04 $218,079 - $682,978
169,054 Added 56.61%
467,658 $617,000
Q4 2021

Feb 14, 2022
SELL
$3.45 - $6.05 $212,230 - $372,171
-61,516 Reduced 17.08%
298,604 $1.15 Million
Q3 2021

Nov 15, 2021
BUY
$5.53 - $9.28 $1.99 Million - $3.34 Million
360,120 New
360,120 $2.01 Million

Others Institutions Holding AVRO

# of Institutions
1
Shares Held
559K
Call Options Held
0
Put Options Held
0
View Full List

About AVROBIO, Inc.

AVRO Quotes by TradingView
  • Ticker AVRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,773,900
  • Description
  • AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...
More about AVRO
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email